Enzon Pharmaceuticals Inc (NASDAQ:ENZN)
During the Trading Day
| 3.16 |  +0.09 / +2.93% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 3.16 |  0.00 / 0.00% |
Volume: 10.6K |
Latest ENZN News | Press Releases
| ENZN July Options Begin Trading May 20 / TheStreet.com |
Today’s Trading
| Previous close | 3.07 |
| Today’s open | 3.07 |
| Day’s range | 3.04 - 3.17 |
| Volume | 134,663 |
| Average volume (3 months) | 325,356 |
| Market cap | $134.1M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | +85.00% |
| Earnings growth (this year) | +666.67% |
| Earnings growth (next 5 years) | +53.00% |
| Revenue growth (last year) | -1.10% |
| P/E ratio | NM |
| Price/Sales | 4.86 |
| Price/Book | 1.73 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PTXPernix Therapeutics ... | +0.03 | +0.84% |
| APPAA.P. Pharma Inc | -0.02 | -3.41% |
| GENTGentium SpA | -0.30 | -3.41% |
| AVEOAveo Pharmaceuticals... | +0.04 | +1.50% |
Data as of 4:00pm ET, 05/23/2013
Financials
| Last reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $42.6M |
| Annual profit (last year) | -$2.8M |
| Net profit margin | -6.53% |
Profile
Sector Health Technology |
Industry Biotechnology |
Director, Chief Executive & Operating Officer Geordie W. Hebard, III, MBA |
Senior Vice President-Research & Development Charles D. Conover, PhD, MBA |
Corporate headquarters Piscataway, New Jersey |
Forecasts
